10 assets in Diffuse Glioma, H3 G34 Mutant

Therapeutic assets addressing Diffuse Glioma, H3 G34 Mutant, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Everolimus Diffuse Glioma, H3 G34 Mutant	Nationwide Children's Hospital	P2	CCC (53)
Ribociclib Diffuse Glioma, H3 G34 Mutant	Nationwide Children's Hospital	P2	CCC (53)
Pegargiminase Diffuse Glioma, H3 G34 Mutant	Sabine Mueller, MD, PhD	P1/2	CCC (48)
Avutometinib Diffuse Glioma, H3 G34 Mutant	Institute of Cancer Research, United Kingdom	P1/2	CC (45)
Defactinib Diffuse Glioma, H3 G34 Mutant	Institute of Cancer Research, United Kingdom	P1/2	CC (45)
Amivantamab-Vmjw Diffuse Glioma, H3 G34 Mutant	Institute of Cancer Research, United Kingdom	P1	CC (41)
Azacitidine Diffuse Glioma, H3 G34 Mutant	Andrew P. Groves	P1	CC (41)
Nivolumab Diffuse Glioma, H3 G34 Mutant	Andrew P. Groves	P1	CC (41)
Vipivotide Tetraxetan Diffuse Glioma, H3 G34 Mutant	Memorial Sloan Kettering Cancer Center	P1	CC (41)
Triapine Diffuse Glioma, H3 G34 Mutant	National Cancer Institute (NCI)	P1	NR ()